Show Notes
Most of the research done on psilocybin has happened at elite institutions with carefully selected participants. Dr. Matthew Hicks did something different.
He ran the first clinical trial ever conducted inside a state-regulated psychedelic program. He focused on a low-income population that clinical trials have systematically failed to reach and that public payers have systematically failed to serve. And he did it for a fraction of the cost and timeline of a typical federal trial.
The findings are striking. A group treatment format that cut the cost of care by more than half. Meaningful drops in severe depression scores across the cohort. And one of the strongest measured outcomes was something the team didn't expect going in: participants' ability to function socially.
In this episode, Matt and Sam dig into the design choices behind the study, what surprised them most, the follow-up study Matt wants to fund next, and why this work is exactly the kind of evidence that could move the needle on Medicaid coverage for psilocybin therapy.
This is the kind of research that's not just asking "does this work." It's asking "does this work for the people who actually need it most, in a system that could actually pay for it." That's the question that defines the next phase of psychedelic policy.
About the Guest Dr. Matthew Hicks is a naturopathic doctor, an Oregon-licensed psilocybin facilitator, and a member of the Oregon Psilocybin Advisory Board. He's the founder of Synaptic Institute, one of Oregon's leading facilitator training programs, and was the lead investigator on the first clinical trial of psilocybin therapy conducted within Oregon's state-regulated program.
Resources Mentioned Synaptic Institute Oregon Psilocybin Services Program Study: Low-Income Group Psilocybin Assisted Therapy for Depression The Center for Psychedelic Policy
Sponsors: Tricycle Day, the leading psychedelic newsletter Althea, the trusted guide to legal psychedelic care in Oregon and Colorado
More from Ground Game
Amy Charlesworth spent 16 years in the Army before she found herself suicidal, having exhausted every conventional treatment the VA system had to offer. A single retreat experience with psilocybin changed that trajectory, and she's spent the years since as a licensed Oregon facilitator whose practice centers on veterans and first responders.
Senator Jeff Steinborn didn't know much about psilocybin therapy when a constituent called him the week before the 2024 legislative session. What followed ended with New Mexico becoming the first state legislature in the country to pass a psilocybin access program. SB 219 passed through the Legislature by a large margin, but the path wasn't always certain.
Amanda Gow didn't set out to build a psilocybin service center. She set out to build a mental health clinic that uses psilocybin as a tool.
Retired police lieutenant and Law Enforcement Action Partnership (LEAP) Executive Director Diane Goldstein joins Sam Chapman to discuss drug policy reform, the role of psychedelics in addressing law enforcement trauma, and LEAP's advocacy for psychedelic access and mental health support. The conversation also covers the fiscal case for legal psychedelic access and the broader psychological and societal costs of current drug policy.
To launch Ground Game, Sam Chapman speaks with Dr. Adie Rae, co-director of the Open Psychedelic Evaluation Nexus, the team at the center of a historic $3.3 million NIDA grant to track outcomes in Oregon's legal psilocybin program.